Biofrontera (NASDAQ:BFRI) Trading Down 1.7% – Here’s What Happened

Posted by Geri Gentry on Jul 10th, 2026

Biofrontera Inc. (NASDAQ:BFRI – Get Free Report)’s share price fell 1.7% during trading on Wednesday . The company traded as low as $1.05 and last traded at $1.14. 594,075 shares traded hands during mid-day trading, an increase of 86% from the average session volume of 319,380 shares. The stock had previously closed at $1.16.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BFRI. Zacks Research downgraded shares of Biofrontera from a “hold” rating to a “strong sell” rating in a research report on Friday, July 3rd. Weiss Ratings downgraded shares of Biofrontera from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Read Our Latest Report on BFRI

Biofrontera Stock Performance

The company has a debt-to-equity ratio of 0.78, a current ratio of 1.20 and a quick ratio of 1.09. The company’s fifty day moving average price is $0.97 and its 200 day moving average price is $0.92. The company has a market cap of $14.08 million, a PE ratio of -1.13 and a beta of 0.81.

Biofrontera (NASDAQ:BFRI – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.29). Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%.The firm had revenue of $10.08 million during the quarter, compared to the consensus estimate of $10.25 million. On average, equities research analysts predict that Biofrontera Inc. will post -0.3 earnings per share for the current year.

Institutional Trading of Biofrontera

An institutional investor recently raised its stake in Biofrontera stock. Geode Capital Management LLC raised its holdings in Biofrontera Inc. (NASDAQ:BFRI – Free Report) by 54.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.08% of the stock is owned by institutional investors and hedge funds.

Biofrontera Company Profile

(Get Free Report)

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.